These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 24640618)

  • 41. Evaluating online direct-to-consumer marketing of genetic tests: informed choices or buyers beware?
    Geransar R; Einsiedel E
    Genet Test; 2008 Mar; 12(1):13-23. PubMed ID: 18373401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. This Article Makes You Smarter! (Or, Regulating Health and Wellness Claims).
    Duranske S
    Am J Law Med; 2017 Mar; 43(1):7-55. PubMed ID: 29086609
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluating the evidence: direct-to-consumer screening tests advertised online.
    Lovett KM; Mackey TK; Liang BA
    J Med Screen; 2012 Sep; 19(3):141-53. PubMed ID: 23093732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gatekeepers or intermediaries? The role of clinicians in commercial genomic testing.
    McGowan ML; Fishman JR; Settersten RA; Lambrix MA; Juengst ET
    PLoS One; 2014; 9(9):e108484. PubMed ID: 25259512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Personal genomics in Greece: an overview of available direct-to-consumer genomic services and the relevant legal framework.
    Kechagia S; Mai Y; Vidalis T; Patrinos GP; Vayena E
    Public Health Genomics; 2014; 17(5-6):299-305. PubMed ID: 25278084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service.
    Downing NS; Ross JS
    JAMA; 2014 Feb; 311(8):793-4. PubMed ID: 24474248
    [No Abstract]   [Full Text] [Related]  

  • 47. Advancing regulatory science to bring novel medical devices for use in emergency care to market: the role of the Food and Drug Administration.
    Scully CG; Forrest S; Galeotti L; Schwartz SB; Strauss DG
    Ann Emerg Med; 2015 Apr; 65(4):400-3. PubMed ID: 25128009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Telehealth physician oversight over direct to consumer testing: doctors working with patients towards patient empowerment.
    Chung R
    Telemed J E Health; 2012 Jun; 18(5):354-9. PubMed ID: 22545797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Who Knows What, and When?: A Survey of the Privacy Policies Proffered by U.S. Direct-to-Consumer Genetic Testing Companies.
    Hazel JW; Slobogin C
    Cornell J Law Public Policy; 2018; 28(1):35-66. PubMed ID: 30840416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. General practitioner attitudes to direct-to-consumer genetic testing in New Zealand.
    Ram S; Russell B; Gubb M; Taylor R; Butler C; Khan I; Shelling A
    N Z Med J; 2012 Oct; 125(1364):14-26. PubMed ID: 23242394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Personal utility is inherent to direct-to-consumer genomic testing.
    Chung MW; Ng JC
    J Med Ethics; 2016 Oct; 42(10):649-52. PubMed ID: 27250638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value.
    Mathews R; Hall W; Carter A
    Addiction; 2012 Dec; 107(12):2069-74. PubMed ID: 22510165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulating (for the benefit of) future persons: a different perspective on the FDA's jurisdiction to regulate human reproductive cloning.
    Javitt GH; Hudson K
    Utah Law Rev; 2003; 2003(4):1201-29. PubMed ID: 15622618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Legislation on direct-to-consumer genetic testing in seven European countries.
    Borry P; van Hellemondt RE; Sprumont D; Jales CF; Rial-Sebbag E; Spranger TM; Curren L; Kaye J; Nys H; Howard H
    Eur J Hum Genet; 2012 Jul; 20(7):715-21. PubMed ID: 22274578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Riskier than we think? The relationship between risk statement completeness and perceptions of direct to consumer advertised prescription drugs.
    Davis JJ
    J Health Commun; 2000; 5(4):349-69. PubMed ID: 11191018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Direct-to-consumer advertising: its effects on stakeholders.
    Montoya ID; Lee-Dukes G; Shah D
    J Allied Health; 2008; 37(2):116-20. PubMed ID: 18630788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing.
    Yim SH; Chung YJ
    Genomics Inform; 2014 Dec; 12(4):151-5. PubMed ID: 25705152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current Policy Challenges in Genomic Medicine.
    Klein RD
    Clin Chem; 2020 Jan; 66(1):61-67. PubMed ID: 31699701
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Limits of FDA's Authority to Regulate Clinical Research Involving High-Throughput DNA Sequencing.
    Evans BJ
    Food Drug Law J; 2015; 70(2):259-87, ii. PubMed ID: 26302600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDA's compassion for desperate drug companies.
    Annas GJ
    Hastings Cent Rep; 1990; 20(1):35-7. PubMed ID: 2179165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.